Showing results (161-170 of 181) with videos related to
Sort By:
Pageof 19
Journal of the National Cancer Institute|March 16, 1988
Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188L R Zacharski, T E Moritz, L A Baczek, et al.Journal of the American Academy of Dermatology|May 6, 2021
Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studiesKim Papp, Jacek C Szepietowski, Leon Kircik, et al.Dermatology and Therapy|October 22, 2025
Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with VitiligoDavid Rosmarin, Amit G Pandya, Thierry Passeron, et al.Science Advances|May 31, 2024
The KAT module of the SAGA complex maintains the oncogenic gene expression program in <i>MYCN-</i>amplified neuroblastomaClare F Malone, Nathaniel W Mabe, Alexandra B Forman, et al.European Journal of Medical Genetics|July 22, 2018
NRXN1 deletion syndrome; phenotypic and penetrance data from 34 familiesMaryam Al Shehhi, Eva B Forman, Jacqueline E Fitzgerald, et al.Cancer Research|November 18, 2022
Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK InhibitorsClare F Malone, Minjee Kim, Gabriela Alexe, et al.JAMA|February 27, 1981
Effect of warfarin on survival in small cell carcinoma of the lung. Veterans Administration Study No. 75L R Zacharski, W G Henderson, F R Rickles, et al.The British Journal of Dermatology|March 28, 2019
Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trialsG B E Jemec, M M Okun, S B Forman, et al.Experimental Dermatology|May 18, 2021
Insights into adult atopic dermatitis heterogeneity derived from circulating biomarker profiling in patients with moderate-to-severe diseaseJonathan T Sims, Ching-Yun Chang, Richard E Higgs, et al.Journal of the American Academy of Dermatology|February 8, 2018
Baricitinib in adult patients with moderate-to-severe atopic dermatitis: A phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose studyEmma Guttman-Yassky, Jonathan I Silverberg, Osamu Nemoto, et al.Pageof 19